The efficacy of transdermal sumatriptan is too low for general use in migraine

Headache

Volumn 53, Issue 5, 2013, Pages 842-843

  Tfelt Hansen, Peer Carsten ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

DRUG EFFECT; DRUG EFFICACY; LETTER; MIGRAINE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANALGESICS; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; SUMATRIPTAN;

EID: 84876812199     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12061     Document Type: Letter

References (7)

1. Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M,. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012; 52: 1402-1410.
2. 1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
3. Derry CJ, Derry S, Moore RA,. Sumatriptan (oral administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2) CD008615.
4. International Headache Society Clinical Trial Subcommittee. Guidelines for controlled trials of drugs in migraine. Second edition. Cephalalgia. 2000; 20: 765-786.
5. Tfelt-Hansen P, Pascual J, Ramadan N, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012; 32: 6-38.
6. TM: A novel transdermal formulation of sumatriptan. Headache. 2009; 49: 817-825.
7. Tfelt-Hansen P,. Parenteral vs. Oral sumatriptan and naratriptan: Plasma levels and efficacy in migraine. A comment. J Headache Pain. 2007; 8: 273-276.